You are once again deliberately misrepresenting what was actually said. Show me a single transcript where management stated any of the things you’re claiming. You can’t, because they never did.
What management has consistently said on prior calls is that the company was exploring strategic alternatives, engaging advisors, and evaluating interest — not that a deal was guaranteed or happening immediately. There’s a massive difference between “exploring a sale” and “a transaction closes tomorrow.”
Clearly some of you have never been involved in an actual M&A process. First, you retain advisors and prepare the CIM (Confidential Information Memorandum). That process alone can take months between financial preparation, operational review, editing, legal review, and management input. Then the bankers — in this case Jefferies — begin contacting potentially interested parties. Some companies pass immediately. Some express interest and later walk away. Others require extensive diligence, financing, or board approval before moving forward.
That is literally how acquisitions work.
Nasrat previously stated the company wasn’t formally “up for sale” yet while preparations were still underway. Once a process officially begins, timelines become unpredictable. Buyers change their minds. Financing conditions change. Boards reject deals. Interested parties can disappear and new ones can emerge later. None of that means management was “lying.” It means this is a real-world transaction process, not fantasy football.
What’s ironic is that the same people screaming “fraud” ignore the company’s actual progress. Elite has improved profitability, reduced debt, expanded manufacturing capabilities, increased revenues, and continues advancing its pipeline. The company is in a significantly stronger position operationally than it was a few years ago. That matters whether a sale happens or not.
And that’s the part the doom crowd keeps missing: Elite does not need to sell tomorrow to create shareholder value. The business is growing. The fundamentals have improved. If a strategic transaction happens, great. If not, the company can continue executing and increasing value organically.
People acting like every delay proves some conspiracy simply do not understand how long M&A processes can take — especially in pharma, where diligence, manufacturing review, regulatory exposure, and financing all add complexity.
If you’re actually long and paying attention to the fundamentals instead of daily message-board drama, the next 3–12 months could be very rewarding. Ps PLEASE TAKE YOUR MEDS.
Market Data 
Markets 
